Download MendeleyComplex crystal structure determination and anti-non-small-cell lung cancer activity of the Hsp90 N inhibitor Debio0932.
Qin, W., Yu, F., Zhou, H., Li, P., Zhou, F., Li, H.J., He, C.X., Xing, L., Zhou, X., Zhao, D., Li, P.Q., Jin, X., Wang, Q.S., He, J.H., Cao, H.L.(2021) Acta Crystallogr D Struct Biol 77: 86-97
- PubMed: 33404528
- DOI: https://doi.org/10.1107/S2059798320014990
- Primary Citation of Related Structures:
6LR9 - PubMed Abstract:
Debio0932 is a promising lead compound in phase I clinical trials targeting the N-terminal ATP-binding pocket of the molecular chaperone heat-shock protein 90 (Hsp90 N ). The absence of a crystal structure of the Hsp90 N -Debio0932 complex, however, has impeded further structural optimization of Debio0932 and understanding of the molecular-interaction mechanism. Here, a high-resolution crystal structure of the Hsp90 N -Debio0932 complex was successfully determined (resolution limit 2.20 Å; PDB entry 6lr9) by X-ray diffraction and the molecular-interaction mechanism was analysed in detail, which suggested that Debio0932 suppresses cancer cells by accommodating itself in the ATP-binding pocket of Hsp90 N , disabling its molecular-chaperone capability. The results of a thermal shift assay (ΔT m = 8.83 ± 0.90°C) and isothermal titration calorimetry (K d = 15.50 ± 1.30 nM) indicated strong binding and favourable thermodynamic changes in the binding of Hsp90 N and Debio0932. Based on the crystal structure of the complex and on molecular-interaction analysis, 30 new Debio0932 derivatives were designed and nine new derivatives exhibited increased binding to Hsp90 N , as determined by molecular-docking evaluation. Additionally, Debio0932 suppressed cell proliferation (IC 50 values of 3.26 ± 2.82 µM for A549, 20.33 ± 5.39 µM for H1299 and 3.16 ± 1.04 µM for H1975), induced cell-cycle arrest and promoted apoptosis in three non-small-cell lung cancer (NSCLC) cell lines. These results provide novel perspectives and guidance for the development of new anti-NSCLC drugs based on the lead compound Debio0932.
Organizational Affiliation:
Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Shaanxi Key Laboratory of Brain Disorders, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, People's Republic of China.
